RAPT Therapeutics CEO Brian Wong walks us through the company's focus on inflammatory conditions, including a lead clinical program targeting IgE, and a next-generation CCR4 in preclinical development
Sep 9, 2025
1 min read
He describes the lead program, RPT-904, which is designed to have a longer half-life and to be more selective than omalizumab. Plus, the science behind CCR4 antagonism and how RAPT is taking learnings from an ealier program into a next-generation one.
Coverage brought to you by:
.png){kind=logo}